LAMIVUDINA/TENOFOVIR DISOPROXIL CIPLA 300mg / 245mg film-coated tablets medication leaflet

J05AR12 • lamivudine + tenofovir disoproxil • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

The combination of lamivudine and tenofovir disoproxil is used for the treatment of HIV-1 infection and chronic hepatitis B. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.

The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, diarrhea, fatigue, or headaches. In rare cases, lactic acidosis, renal failure, or severe allergic reactions may occur.

This combination is not recommended for patients with severe renal impairment or hypersensitivity to any of the components.